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Introduction:  With the application of genetic testing to contemporary medical diagnostics and practice, it 
has become apparent that the phenotypes of many disorders are modulated by host genetic factors.  For 
example, the susceptibility to and progression of non-alcoholic fatty liver disease [NAFLD] have been 
associated with the p. I148M variant in the patatin-like LA3 phosphatase [PNPLA3] gene and p. E167K 
variant of transmembrane 6 super family 2 [TM6SF2] (1,2).  In contrast, susceptibility to idiosyncratic drug-
induced liver injury (DILI) , a rare form of liver disease, has been associated primarily with genes that 
influence innate or adaptive immune responses(3,4).
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The aim of the current study, was to determine whether selected single nucleotide polymorphisms (SNPs) 
unrelated to the HLA region or other immune pathways, including those associated with NAFLD, may 
influence development, severity, or outcomes of DILI.  
Methods: Thirteen variants previously associated with NAFLD and/ selected other liver diseases were 
tested in 832 Caucasian DILI cases and 10,397 Caucasian population controls (Table 1)(5).  DILI cases 
were attributed to multiple agents (177 individual drugs) and 56 cases due to HDS products. All cases 
had DILIN causality scores equal to or higher than probable [judged 51-100% likely due to a drug].  None 
of the subjects from DILIN had been enrolled as acute cases, within 14 days of onset.  Eight variants 
were imputed from the most recent genome-wide association study(5) and 4 additional variants (identified 
by *) were directly genotyped only in DILI cases, except for the hydroxysteroid dehydrogenase 17B13 
[HSD17B13] splice variant, which was typed only in a subset of the DILI cases (n=384, identified by **).  
For the latter variants, the allele frequencies for European (non-Finnish) control samples in the Gnomad 
database were used (http://gnomad.broadinstitute.org/). 
The DILI cases were also categorized by severity and chronic DILI.  Chronic DILI was defined as 
evidence of ongoing liver injury 6 months after DILI onset, as described (3,5).  The significance was tested 
by linear regression or logistic regression, depending on the nature of trait.  For genotyped variants and 
binary traits, the associations were compared to European control samples listed in Gnomad database 
and by Fisher exact test. 
Any variant that passed the Bonferroni threshold of P <0.0004 (0.05/13) was considered a significant 
association.  Follow-up analyses were done for the most strongly associated variants by testing in an 
independent Caucasian cohort of 974 DILI cases from the International Drug-Induced Liver Injury 
Consortium [iDILIC] (5) and in African Americans (169 DILIN cases vs 1,314 controls) and Hispanic 
cohorts (109 DILIN cases and 718 controls) (5).
Results: None of the variants proved to be significantly associated with DILI as phenotype (Table 1), nor 
with any of the selected severity traits (Table S1).  Among the variants studied, rs1421085, found in the 
FTO gene, showed a marginal protective effect (OR= 0.8, 95%CI [0.77-0.95], P=0.005), [similar trend 
also in Hispanic and African-American cohort], but Caucasian replication cases showed higher frequency 
of the variants (Table S1).  
Conclusion:  None of the genetic polymorphisms tested was significantly associated with the risk of 
development, severity or outcome of DILI.  These data suggest that single nucleotide polymorphisms 
[SNPs] implicated in common liver diseases such as NAFLD do not play a substantial role in DILI 
pathogenesis across agents.  However, it remains possible that these variants could be involved with DILI 
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risk or outcome due to a single drug, which will require the evaluation of larger numbers of bona fide 
cases due to specific drugs.  In addition, rare variants may play a role in DILI pathogenesis, but additional 
studies using whole exome or genome testing are required.  
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Table 1. SNPs investigated in DILIN Caucasian DILI cases and population controls.
Gene 
name
Genetic 
variant
Coding
DNA
change
Amino 
acid 
change
Putative effect of 
variant in NAFLD
DILI 
Case 
MAF
Control 
MAF
P
rs738409 444C>G I148M Increased 
hepatocyte 
triglyceride 
content
21.1% 23.4% 0.5PNPLA3
rs6006460* 1531G>T S453I Lower-than-
average hepatic 
triglyceride 
accumulation
0.06% 0.02% 0.2
TM6SF2 rs58542926 499A>G E167K Elevated 
AST/ALT, 
increased hepatic 
triglyceride levels, 
6.9% 7.5% 0.37Au
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decreased serum 
cholesterol
rs10401969
613+80A>G Intron
Lower hepatic 
TM6SF2 mRNA 
levels correlate 
with larger 
hepatocellular 
lipid droplets
6.9% 7.7% 0.2
LIPA rs116928232* 894G>A E8SJM Cholesterol ester 
storage disease 
often resulting in 
fibrosiscirrhosis
0.1% 0.1% 1
IFNL4 rs12979860*
151-152G>A Intron
Increased degree 
of hepatic 
inflammation and 
fibrosis
32.3% 32.0% 0.9
rs1800562 845G>A C282Y Increased hepatic 
iron uptake, 
associated with 
greater NAFLD 
risk/severity
6.0% 5.5% 0.74HFE
rs1799945 187C>G H63D Increased hepatic 
iron uptake, 
associated with 
greater NAFLD 
risk/severity
15.3% 15.9% 0.8
HMOX1 rs2071746* -413A>T
Affects 
promoter
Higher HMOX1 
activity correlated 
with less frequent 
and less severe 
NAFLD
42.7% 43.5% 0.9
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FTO rs1421085 46-43098T>C
Affects 
repressor
Adipocytic 
phenotype shift 
from beige 
(energy-
dissipating) to 
white (energy-
storing)
38.2% 41.7% 0.005
GNPAT rs11558492 1556A>G
D519G
Worsened iron 
overload in 
patients with HFE 
genetic variations
21.1% 23.3% 0.7
SERPINA1 rs28929474 1096G>A
E342K
Associated with 
deficiency of 
alpha-1 antitrypsin 
and with 
increased risk of 
liver diseases
2% 2% 0.73
HSD17B13 rs72613567** 4:88231392;T>TA
Splice 
variant
Associated with a 
reduced risk of 
chronic liver 
disease and of 
progression from 
steatosis to 
steatohepatitis
28% 27% 0.52
Abbreviations used: MAF, minor allele frequency; NAFLD, non-alcoholic liver disease
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